Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Therapeutic Roles of Car T Cells in Infectious Diseases: Clinical Lessons Learnt From Cancer Publisher Pubmed



Mohammadi M1, 2 ; Akhoundi M1 ; Malih S3, 4 ; Mohammadi A5, 6 ; Sheykhhasan M7, 8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
  2. 2. Department of Developmental Biology, University of Science and Culture, Tehran, Iran
  3. 3. Department of Radiology, University of Wisconsin-Madison, Madison, WI, United States
  4. 4. Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  5. 5. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
  7. 7. Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
  8. 8. Department of Mesenchymal Stem Cells, The Academic Center for Education, Culture and Research, Qom, Iran

Source: Reviews in Medical Virology Published:2022


Abstract

Cancer immunotherapy has made improvements due to the advances in chimaeric antigen receptor (CAR) T cell development, offering a promising treatment option for patients who have failed to respond to traditional treatments. In light of the successful use of adoptive CAR T cell therapy for cancer, researchers have been inspired to develop CARs for the treatment of other diseases beyond cancers such as viral infectious diseases. Nonetheless, various obstacles limit the efficacy of CAR T cell therapies and prevent their widespread usage. Severe toxicities, poor in vivo persistence, antigen escape, and heterogeneity, as well as off-target effect, are key challenges that must all be addressed to broaden the application of CAR T cells to a wider spectrum of diseases. The key advances in CAR T cell treatment for cancer and viral infections are reviewed in this article. We will also discuss revolutionary CAR T cell products developed to improve and enhance the therapeutic advantages of these treatments. © 2022 John Wiley & Sons Ltd.
Other Related Docs
16. Car-Modified T-Cell Therapy for Cancer: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)
19. Car-Nk Cells for Haematological Cancers, Best Practice and Research: Clinical Haematology (2025)
24. Hurdles in Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
28. Genetically Modified Immune Cells Targeting Tumor Antigens, Pharmacology and Therapeutics (2020)
32. Tumor Immunology, Clinical Immunology (2022)
35. Cancer Immunotherapy: Diverse Approaches and Obstacles, Current Pharmaceutical Design (2022)
36. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
39. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
40. Crispr/Cas9 Revitalizes Adoptive T-Cell Therapy for Cancer Immunotherapy, Journal of Experimental and Clinical Cancer Research (2021)
43. Gene Therapy Clinical Trials, Where Do We Go? an Overview, Biomedicine and Pharmacotherapy (2022)
50. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)